02/09/2022
🔸立即預約【嘉仁視像會診】https://bit.ly/3AJYHxF 🔸
【中大醫學團隊研新冠口服藥或可降低確診者入院風險】
中大醫學院團隊近日發表最新研究,分析咗今年年初到公立醫院指定診所求診嘅9萬餘名新冠患者數據,當中有6.2%和5.2%病人分別獲處方默沙東口服藥和輝瑞口服藥。跟進病人30日後,大數據分析咗有食同無食新冠口服藥嘅差別,發現輝瑞口服藥(nirmatrelvir/ritonavir)可以減少病人約20%嘅入院風險,而默沙東口服藥(Molnupiravir)就冇顯着降低有關風險。
當然大家要留意是次研究對象為現實世界的病人。考慮到兩款藥物供港次序有先後、藥物相互作用等因素,團隊已經採用先進嘅統計方法盡量平衡。
另外,醫管局呼籲,病人即使有處方服食新冠口服藥,亦應留意身體情况同服畢全個療程;快速測試「轉陰」後亦唔好停藥。
嘉仁嘅藥劑部都備有以上兩款新冠口服藥。如果您剛確診新冠肺炎,歡迎預約嘉仁視像會診及送藥服務,我哋嘅醫生會根據您的臨床情況作出專業判斷,為您提供最適切治療。
想知道更多健康資訊,記得like & follow我地Facebook同Instagram喇!
☎️電話:2216 9388
📱WhatsApp:https://bit.ly/3ya44E0
🏥地址:中環皇后大道中35號
🌐瀏覽「嘉仁專科醫療」網頁👉🏼https://www.yourhealth.com.hk
#嘉仁專科醫療
#視像會診
#線上睇醫生
【本港大型新冠口服藥效果研究】本港公立醫院自第五波疫情高峰起處方兩款新冠口服藥。中大醫學院團隊最新研究發現,與沒有使用口服藥物的病人比較,輝瑞口服藥(nirmatrelvir/ritonavir)能減少病人約20%的入院風險,而默沙東口服藥(Molnupiravir)則沒有顯着降低有關風險。兩款藥物與降低需接受深切治療、使用呼吸機和死亡風險,沒有關聯。
團隊分析了今年2月至3月期間,到公立醫院指定診所求診的9萬多名新冠患者數據,當中有6.2%和5.2%病人分別獲處方默沙東口服藥和輝瑞口服藥。團隊跟進病人情況30天,並利用大數據分析獲得上述結果。
值得注意的是,研究分析的是現實世界的病人數據。受藥物供港次序,以及輝瑞口服藥與多種藥物有交互作用等因素影響,默沙東口服藥多處方予年長及體弱病患。團隊在分析時已透過先進的統計方法盡量平衡相關因素。
研究全文:https://bit.ly/3Q4KgJg
【Large-scale study to compare COVID oral drugs’ effectiveness in HK】Since the peak of the 5th wave of the epidemic, public hospitals in Hong Kong have prescribed 2 types of oral medicines for COVID-19 patients. A recent study by a team from CU Medicine found that Pfizer's oral drug (nirmatrelvir/ritonavir) can reduce the risk of hospital admission by about 20%, while MSD’s oral drug (Molnupiravir) did not significantly reduce the risk, compared with patients who did not use oral drugs. Neither drug was associated with a reduced risk of intensive care unit admission, invasive mechanical ventilator uses or death.
The team analysed the data of more than 90,000 COVID-19 patients who visited the designated clinics of public hospitals from February to March this year. Among them, 6.2% and 5.2% of the patients were prescribed the MSD’s oral drug and Pfizer’s oral drug, respectively. The team followed up the patients for 30 days and used big data analysis to obtain these results.
It is worth noting that the study analysed real-world patient data. Due to factors such as the availability of drugs in Hong Kong and the multiple drug-drug interactions associated with Pfizer's oral drug, MSD's oral drugs were often prescribed to frail patients (i.e. elder patients with more comorbidities). The team has tried to balance the relevant factors through sophisticated statistical approaches in the analysis.
Full article of the study: https://bit.ly/3Q4KgJg